Wysa的AI心理健康门户：450万用户，获FDA认证，覆盖NHS 31项服务

做的是什么生意

Wysa is an AI-guided mental-health platform: a freemium chatbot offering CBT-based support, plus a digital 'front door' product that employers and public health systems use for triage, self-referral and waitlist care.

启动资金：$9.4M raised before July 2022, then a $20M all-equity Series B led by HealthQuad with British International Investment; a £5.3M Wellcome grant followed in February 2026.

起因

Wysa was conceived in 2016 after co-founder Jo Aggarwal fell into a deep depression and saw how gated professional help was; she and Ramakant Vempati built an AI companion in India offering 'early engagement and a safe space' where people can talk anonymously about what is bothering them.

经过

Wysa grew to 4.5 million users across 65 countries and more than 400 million conversations, with about 80% of revenue from enterprise clients such as Accenture, Colgate-Palmolive, Aetna International and Swiss Re. In May 2022 the FDA granted Breakthrough Device designation, and the UK's NHS and Singapore's Ministry of Health deployed it. By March 2025 it was live across 31 NHS Talking Therapies services, facilitating more than 117,000 self-referrals and supporting over 36,000 people on waitlists, according to Whittington Health NHS Trust.

结果

Wysa is expanding from chatbot vendor into a broader care company - acquiring US physical-therapy provider Kins and psychiatric-care provider April Health, both described as Wysa companies - and in February 2026 Wellcome awarded £5.3 million to adapt its clinically validated intervention for adolescent girls in rural India.

可借鉴之处

将AI放在瓶颈处——护理门户：自动化分诊、自助和候诊支持，可腾出人类治疗师处理重症病例，并通过临床验证赢得信任。